Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

Although significant progress has been made in the treatment and management of patients with FL, several challenges remain, including the need to develop better prognostic models and markers for ...

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...

Show More From the Department of Medicine, Harvard Medical School; Department of Medical Oncology, Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center Cancer Center; Massachusetts ...

More than 60 percent of breast cancer cases involve defects in the same biochemical chain of events within cancer cells-- known as the PI3 kinase (PI3K) pathway--but efforts to develop therapies ...

An aggressive breast cancer lacking common drug targets, triple-negative breast cancer may be countered by oridonin, a ...

Study in JCI identified breast tumor protein signature that predicts poor outcome after treatment. Combining a PI3K pathway inhibitor with endocrine therapy may help prevent estrogen-dependent breast ...

SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to a randomized study reported here.

Calistoga Pharmaceuticals Inc., a Seattle-based drug development startup focused on oncology and inflammation, has raised $5.2 million in additional Series A funding, raising the round total to $26.2 ...